Gilead Sciences, Inc. Share Price and Company Fundamentals
Last traded: Last Friday at 8:00 PM
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Key Metrics
PE ratio
19.31
PB ratio
3.91
Dividend yield
4.61%
Beta
0.35
Market cap
-
Enterprise value
-
Company profile
| Industry / Sector | Drug Manufacturers—General / Healthcare |
|---|---|
| Full time employees | 14400 |
| Website | https://www.gilead.com |
| Mailing address | 333 Lakeside Drive Foster City CA 94404 United States |
| Phone / Fax | 650 574 3000 / 650 522 5853 |
Dividends
Dividend yield
4.61%
Dividend amount
$2.88
Payout ratio
88.07%
5Y Avg. yield
3.69%
Gilead Sciences, Inc. paid $2.88 dividend and the ex-dividend date was 13 Sept 2022.The dividend payout ratio is 88.07%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.GILD dividend payout ratio is between 70-90%. The lower dividend payout ratio is preferrable since it provides company margin to grow the dividends in future.
GILD's forward dividend amount is $2.92 and the forward dividend yield is 4.64%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of Aug 2022, following are the company executives and directors listed on Gilead Sciences, Inc..
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO | 57 | 6.09M |
| Mr. Andrew D. Dickinson | Exec. VP & CFO | 51 | 2.55M |
| Ms. Johanna Mercier | Chief Commercial Officer | 51 | 2.92M |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 58 | 2.68M |
| Ms. Diane E. Wilfong | Sr. VP, Corp. Controller & Chief Accounting Officer | 59 | |
| Ms. Jacquie Ross C.F.A. | VP of Investor Relations | ||
| Ms. Deborah H. Telman | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. | 56 | |
| Ms. Jyoti K. Mehra | Exec. VP of HR | ||
| Dr. Michael Quigley Ph.D. | Sr. VP of Research Biology | ||
| Dr. Linda Slanec Higgins Ph.D. | Sr. VP & Head of External Innovation | 59 |
Profitability and management effectiveness
Profit margin
15.04%
Operating margin
40.36%
Return on assets
10.61%
Return on equity
20.58%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Gilead Sciences, Inc. is and its enterprise value is .
The GILD's stocks Beta value is 0.35 making it 65% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Gilead Sciences, Inc. (NASDAQ:GILD) Frequently Asked Questions
1. What is Gilead Sciences, Inc.'s Stock Symbol?
Gilead Sciences, Inc. trades on NASDAQ under the ticker symbol "GILD".
2. What is Gilead Sciences, Inc.'s stock price today?
One share of GILD stock can currently be purchased for approximately $62.96.
3. How can I contact Gilead Sciences, Inc.?
Gilead Sciences, Inc.'s mailing address is 333 Lakeside Drive Foster City CA 94404 United States. The company can be reached via phone at 650 574 3000.
4. What is Gilead Sciences, Inc.'s official website?
The official website of Gilead Sciences, Inc. is https://www.gilead.com.